文献速递药物不良反应与药物警戒

EudraVigilance药品安全数据库:面向研究与公共卫生防护的公开数据

EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection.
PubMed 文献 · Drug Saf · 2018-01-01

The analysis of safety data from spontaneous reporting systems has a proven value for the detection and analysis of the risks of medicines following their placement on the market and use in medical practice.…

要点

  • EudraVigilance是欧洲经济区药物警戒数据库,管理疑似不良反应的收集与分析。
  • 文献中50%用于描述安全性问题,44%用于分析方法学,6%支持临床视角。

核心结论

  • EudraVigilance扩大数据访问旨在促进获批药品更有效的安全监测并为研究和医患提供更多疑似不良反应信息。

主要发现

  • 50%的出版物用数据描述安全性问题,44%用于分析药物警戒活动方法学,6%用于支持临床视角。

关键数值与推荐

  • 学术研究机构可申请更广泛数据集用于健康研究。

临床怎么用

  • 临床药学人员可利用公开的疑似不良反应数据支持药品安全监测与研究。
  • 学术机构可申请扩展数据集开展药物警戒相关健康研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The analysis of safety data from spontaneous reporting systems has a proven value for the detection and analysis of the risks of medicines following their placement on the market and use in medical practice. EudraVigilance is the pharmacovigilance database to manage the collection and analysis of suspected adverse reactions to medicines authorised in the European Economic Area. EudraVigilance first operated in December 2001, with access to the database being governed by the EudraVigilance access policy. We performed a literature search including data up to December 2016 to demonstrate how the data from EudraVigilance has been used in scientific publications. We describe the results, including by type of publication, research topics and drugs involved. In 50% of the publications, the data are used to describe safety issues, in 44% to analyse methodologies used in pharmacovigilance activities and in 6% to support clinical perspectives. We also outline a description of the use of the database by the European Union regulatory network. Driven by the full implementation of the 2010 pharmacovigilance legislation, EudraVigilance has undergone further enhancements together with a major revision of its access policy, taking into account the use of the new individual case safety report standard developed by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and the International Organization for Standardization. The aim of the broadened access is to facilitate more effective safety monitoring of authorised medicines, to make more data available for research and to provide better access to information on suspected adverse reactions for healthcare professionals and patients. In November 2017, the new full functionalities of EudraVigilance were launched, including the extensive web access to data on suspected adverse drug reactions and the possibilities for academic research institutions to request a more extensive dataset for the purposes of health research. The main objective of this article is to describe the new access to the database together with the opportunities that this new access can bring for research. It is intended to promote an appropriate use of the data to support the safe and effective use of medicines.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Postigo R, Brosch S, Slattery J, et al. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. Drug Saf. 2018. PMID: 29520645. doi:10.1007/s40264-018-0647-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。